Re: New Compounds (reply and contact info)

[Guest guest]

My apologies, Bill, I know since my viral load went sky high I don't remember a

whole lot from one day to the next, which is why

I e-mailed UCLA as soon as I read your post. Thank you for the reminder. I did

just hear back from them. If anyone is interested, below is a contact e-mail and

phone number. Sheena

Catechin and naringenin upcoming Phase I clinical trial.

You may want to contact Dr. Sam Wheeler French who is involved with the

research:

Email: sfrench@...

Phone:

> >>

> >> New Compounds Show Promise Against Hepatitis C Infection

> >>

> >> 13 Apr 2011

> >>

> >> Approximately 270-300 million people worldwide are infected with

> >> hepatitis C, and about 1%-2% of the U.S. population is infected. This

> >> infectious disease can lead to scarring of the liver, cirrhosis, and

> >> eventually liver failure. A significant number of infected patients

> >> develop liver disease or cancer. The current standard treatment is

> >> interferon, which has only a 50% success rate. Compounding the 50%

> >> failure rate are severe side effects which lead many people to

> >> discontinue treatment.

> >>

> >> Dr. Wheeler French Jr., MD, PhD, Assistant Professor of Pathology

> >> and Laboratory Medicine at UCLA and researcher at UCLA's Jonsson

> >> Comprehensive Cancer Center, is a liver pathologist who is currently

> >> developing a proteomic-based program to study the development of liver

> >> cancer from hepatitis C viral infection. His most recent study results,

> >> to be presented in an American Society for Investigative Pathology

> >> (ASIP) symposium on " Pathobiology of Liver Injury and Fibrosis " on

> >> Tuesday afternoon, April 12 at Experimental Biology 2011, evaluate the

> >> effects of several flavonoids on hepatitis C viral infection.

> >> Previously, Dr. French has shown that quercetin, a plant-derived

> >> bioflavonoid used by some as a nutritional supplement, attenuates

> >> Hepatitis C virus production with no cell toxicity. In his most recent

> >> research, French and colleagues found that two other bioflavonoids,

> >> catechin and naringenin, displayed antiviral activity on tissue culture.

> >> The next step is to determine through a Phase I Clinical Trial that they

> >> are safe for patients with chronic hepatitis C infection.

> >>

> >> " We now have several new compounds we can test to see if they reduce

> >> virus infection, " said Dr. French. " The positive thing about this family

> >> of compounds is that they are nontoxic, and can be taken at high doses.

> >> Bioflavonoids represent a very promising therapy with very few side

> >> effects that could help millions of people. "

> >>

> >> Source:

> >> Federation of American Societies for Experimental Biology (FASEB)

> >> American Society for Investigative Pathology

> >> ------------------------------------------------------------------------

> >>

> >> Article URL: http://www.medicalnewstoday.com/articles/222183.php

> >>

> >> --

> >> Bill Eastman

> >> www.ke5asu.com/links.html<http://www.ke5asu.com/links.html>

> >>

> >

> >

> >

> >

>

>

> --

> Bill Eastman

> www.ke5asu.com/links.html <http://www.ke5asu.com/links.html>

>